269 related articles for article (PubMed ID: 23240670)
21. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
Ueno Y; Enomoto T; Otsuki Y; Sugita N; Nakashima R; Yoshino K; Kuragaki C; Ueda Y; Aki T; Ikegami H; Yamazaki M; Ito K; Nagamatsu M; Nishizaki T; Asada M; Kameda T; Wakimoto A; Mizutani T; Yamada T; Murata Y
Cancer Lett; 2006 Sep; 241(2):289-300. PubMed ID: 16459017
[TBL] [Abstract][Full Text] [Related]
22. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
24. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
25. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
[TBL] [Abstract][Full Text] [Related]
26. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathology of ovarian cancer.
Sanseverino F; D'Andrilli G; Petraglia F; Giordano A
Anal Quant Cytol Histol; 2005 Jun; 27(3):121-4. PubMed ID: 16121632
[TBL] [Abstract][Full Text] [Related]
29. [Ovarian cancer--modern approach to its origin and histogenesis].
Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
[TBL] [Abstract][Full Text] [Related]
30. [Ovarian carcinoma. Do the subtypes reflect different diseases?].
Köbel M
Pathologe; 2008 Nov; 29 Suppl 2():160-2. PubMed ID: 18709371
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
32. [Heterogeneity of epithelial ovarian carcinomas and their clinical significance].
Noske A
Praxis (Bern 1994); 2014 Jan; 103(3):155-9. PubMed ID: 24468455
[TBL] [Abstract][Full Text] [Related]
33. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
[TBL] [Abstract][Full Text] [Related]
34. TTF-1 expression in primary ovarian epithelial neoplasia.
Graham AD; Williams AR; Salter DM
Histopathology; 2006 May; 48(6):764-5. PubMed ID: 16681695
[No Abstract] [Full Text] [Related]
35. Association of decreased mitochondrial DNA content with ovarian cancer progression.
Wang Y; Liu VW; Xue WC; Cheung AN; Ngan HY
Br J Cancer; 2006 Oct; 95(8):1087-91. PubMed ID: 17047655
[TBL] [Abstract][Full Text] [Related]
36. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
[TBL] [Abstract][Full Text] [Related]
37. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
38. Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
Köbel M; Kalloger SE; Huntsman DG; Santos JL; Swenerton KD; Seidman JD; Gilks CB;
Int J Gynecol Pathol; 2010 May; 29(3):203-11. PubMed ID: 20407318
[TBL] [Abstract][Full Text] [Related]
39. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma.
Takai N; Miyazaki T; Nishida M; Nasu K; Miyakawa I
Int J Mol Med; 2002 Aug; 10(2):211-6. PubMed ID: 12119561
[TBL] [Abstract][Full Text] [Related]
40. [Cytology of ovarian epithelial tumors].
Otsuki T; Yaegashi N
Nihon Rinsho; 2004 Oct; 62 Suppl 10():503-6. PubMed ID: 15535296
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]